PROCEPT BioRobotics (PROCEPT BioRobotics) Cash, Cash Equivalents, Marketable Securities : $225.6 Mil (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is PROCEPT BioRobotics Cash, Cash Equivalents, Marketable Securities?

PROCEPT BioRobotics's quarterly cash, cash equivalents, marketable securities declined from Sep. 2023 ($287.09 Mil) to Dec. 2023 ($257.22 Mil) but then stayed the same from Dec. 2023 ($257.22 Mil) to Mar. 2024 ($225.58 Mil).

PROCEPT BioRobotics's annual cash, cash equivalents, marketable securities declined from Dec. 2021 ($304.32 Mil) to Dec. 2022 ($221.86 Mil) but then increased from Dec. 2022 ($221.86 Mil) to Dec. 2023 ($257.22 Mil).

PROCEPT BioRobotics Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for PROCEPT BioRobotics's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PROCEPT BioRobotics Cash, Cash Equivalents, Marketable Securities Chart

PROCEPT BioRobotics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Cash, Cash Equivalents, Marketable Securities

42.02

100.13

304.32

221.86

257.22

PROCEPT BioRobotics Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial												180.97	149.69	287.09	257.22	225.58

PROCEPT BioRobotics Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

PROCEPT BioRobotics (NAS:PRCT) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

PROCEPT BioRobotics Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of PROCEPT BioRobotics's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

PROCEPT BioRobotics (PROCEPT BioRobotics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » PROCEPT BioRobotics Corp (NAS:PRCT) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

N/A

Address

900 Island Drive, Redwood, CA, USA, 94065

Website

https://www.procept-biorobotics.com

PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. The company's assets are based in the United States. Its revenue is generated from sales of the AquaBeam Robotic System and the accompanying single-use disposable handpieces.

Executives

Alaleh Nouri	officer: SVP, GEN COUNSEL, CORP. SEC.	1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Kevin Waters	officer: Senior VP, CFO	1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Frederic H Moll	director	C/O INTUITIVE SURGICAL INC, 950 KIFER ROAD, SUNNYVALE CA 94086
Wood Morgan Colby	director	C/O PROCEPT BIOROBOTICS CORPORATION, 900 ISLAND DRIVE, REDWOOD CA 94065
Reza Zadno	director, officer: President, CEO	2710 SAND HILL ROAD, SUITE 200, MENLO PARK CA 94025
Hisham Shiblaq	officer: SVP, Commercial Operations	C/O PROCEPT BIOROBOTICS CORPORATION, 900 ISLAND DRIVE, REDWOOD CITY CA 94065
Thomas M Krummel	director	C/O CALIFORNIA WATER SERVICE GROUP, 1720 N. FIRST STREET, SAN JOSE CA 95118
Viking Global Investors Lp	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Parent Gp Llc	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Dragsa 88 Llc	10 percent owner	55 RAILROAD AVE, GREENWICH CT 06830
Rose Sharon Shabet	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Illiquid Investments Sub-master Lp	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Gp Llc	10 percent owner	55 RAILROAD AVENUE, GREENWICH CT 06830
Viking Global Opportunities Portfolio Gp Llc	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
David C. Ott	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901